JPH01151520A - Preventive and remedy for constipation of domestic animal - Google Patents
Preventive and remedy for constipation of domestic animalInfo
- Publication number
- JPH01151520A JPH01151520A JP30972787A JP30972787A JPH01151520A JP H01151520 A JPH01151520 A JP H01151520A JP 30972787 A JP30972787 A JP 30972787A JP 30972787 A JP30972787 A JP 30972787A JP H01151520 A JPH01151520 A JP H01151520A
- Authority
- JP
- Japan
- Prior art keywords
- constipation
- oligosaccharide
- gal
- preventive
- feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010010774 Constipation Diseases 0.000 title claims description 22
- 241001465754 Metazoa Species 0.000 title abstract description 14
- 230000003449 preventive effect Effects 0.000 title abstract description 11
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 8
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract 2
- 244000144972 livestock Species 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 abstract description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 abstract description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 6
- 239000008101 lactose Substances 0.000 abstract description 6
- 102000005936 beta-Galactosidase Human genes 0.000 abstract description 5
- 108010005774 beta-Galactosidase Proteins 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 240000006439 Aspergillus oryzae Species 0.000 abstract description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 239000003651 drinking water Substances 0.000 abstract description 3
- 235000020188 drinking water Nutrition 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract description 2
- 235000020256 human milk Nutrition 0.000 abstract description 2
- 210000004251 human milk Anatomy 0.000 abstract description 2
- 230000003880 negative regulation of appetite Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 5
- 230000032696 parturition Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241001517610 Funa Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、家畜用の便秘予防・治療剤に関するものであ
る。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a preventive and therapeutic agent for constipation for livestock.
家畜、特に豚や牛のような草食性動物は、繊維質の多い
飼料を日常摂取しているため便秘を起こすことは少ない
。しかしながら、妊娠中期から分娩直後までの期間の舟
歌には、顕著な便秘が多発する。そして舟歌の便秘は多
くの場合発熱を引き起こし、泌乳力の低下を招く。した
がって、家畜を飼育する上で舟歌の便秘を予防または治
療し健康状態を良好に保つことは、分娩を軽くシ、分娩
前後の事故を減らすとともに、分娩後の舟歌の回復を早
め、さらには母獣の生育を早めるために重要である。Livestock, especially herbivorous animals such as pigs and cows, are less likely to suffer from constipation because they routinely consume feed high in fiber. However, significant constipation frequently occurs during boating from the second trimester of pregnancy to immediately after delivery. And constipation in funa often causes fever, leading to a decrease in milk production. Therefore, it is important to prevent or treat constipation in the constipation of domestic livestock and maintain good health in order to make childbirth easier, reduce accidents before and after parturition, hasten the recovery of the constipation after parturition, and even improve the mother's health. It is important for speeding up the growth of animals.
従来、家畜の便秘の予防または治療には、便秘薬の注射
、完腸などの処置が行われている。しかしながら、便秘
薬の注射には下痢や食欲減退などの副作用があるほか、
神経過敏な妊娠（または分娩直後の）舟歌に好ましくな
いストレスを与えるという問題もある。また完腸は、効
果が一時的であるばかりか、実施に手間がかかるという
欠点がある。このほか、予防法としては、飼料にふすま
、大麦等を大量に添加して継続的に投与する方法もある
が、飼料コストが高くなるという問題がある。Conventionally, to prevent or treat constipation in domestic animals, treatments such as injection of laxatives and complete intestine have been carried out. However, laxative injections have side effects such as diarrhea and loss of appetite.
There is also the problem of putting undesirable stress on a nervous pregnant woman (or just after giving birth). Furthermore, complete intestine has the disadvantage that not only the effect is temporary, but it is also time-consuming to implement. Other preventive methods include adding large amounts of bran, barley, etc. to feed and administering it continuously, but this poses the problem of increased feed cost.
本発明の目的は、上記従来の方法のような欠点のない、
家畜のための便秘予防・治療の手段を提供することにあ
る。The object of the present invention is to avoid the drawbacks of the above-mentioned conventional methods.
The objective is to provide a means of preventing and treating constipation for livestock.
本発明は、従来の家畜用便秘予防・治療剤のいずれとも
異なる薬剤、すなわち一般弐Ｇ ！１−（Ｇ ｘｉ）ｎ
−Ｇ ｌｃ（但し、式中Ｇａｌはガラクトース残基、Ｇ
ｌｃはグルツース残基、塁は１〜４の整数を、それぞれ
表わす）で示されるオリゴ糖（以下、ガラクトオリゴ糖
という）を有効成分とする家畜用便秘予防・治療剤を提
供するものである。The present invention provides a drug different from any of the conventional constipation prevention and treatment agents for domestic animals, that is, general 2G! 1-(Gxi)n
-G lc (However, in the formula, Gal is a galactose residue, G
The present invention provides a preventive and therapeutic agent for constipation for livestock, which contains as an active ingredient an oligosaccharide (hereinafter referred to as galactooligosaccharide) represented by lc is a gluten residue and base is an integer from 1 to 4, respectively.
ガラクトオリゴ糖は母乳オリゴ糖の主要構成成分であり
、またヒト腸内に生息する有用細菌・ビフィドバクテリ
ウム菌の増殖促進因子として有用であることが知られて
いる。したがって、近年は発酵乳や育児用粉乳へ添加さ
れるなど、種々の分野で利用されるようになった。また
、特開昭６２−１３８１４７号公報には、このオリゴ糖
を家畜の下痢、軟便の防止および体重増加に利用するこ
とが記載されている。しかしながら、ガラクトオリゴ糖
が家畜の便秘の予防と治療に有効であることは従来まっ
たく知られていなかった。Galactooligosaccharides are the main constituents of breast milk oligosaccharides, and are also known to be useful as growth-promoting factors for Bifidobacterium, a useful bacterium that lives in the human intestines. Therefore, in recent years, it has come to be used in various fields, such as being added to fermented milk and powdered milk for infants. Furthermore, JP-A-62-138147 describes the use of this oligosaccharide to prevent diarrhea and loose stools and to increase body weight in livestock. However, it was not previously known that galactooligosaccharides were effective in preventing and treating constipation in livestock.
本発明の家畜用便秘予防・治療剤の有効成分である上記
ガラクトオリゴ糖は、乳糖にアスペルギルス・オリゼの
β−ガラクトシダーゼを作用させる方法（特公昭５８−
２０２６６号公報）、クリプトコツカス属酵母を利用す
る方法（特開昭６０−２５１８９６号公報）等によって
製造することができる。これらの製造法によると、通常
、２０〜６０％程度のガラクトオリゴ糖のほかに未反応
の乳糖を主体とする二糖類および副生するグルコース、
ガラクトース等の単糖類を含有する糖混合物の溶液が得
られる。本発明の家畜用便秘予防・治療剤にはこれをそ
のまま用いることができるが、さらに由来の異なるβ−
ガラクトシダーゼを作用させて未反応乳糖の含有量を下
げたものを用いてもよい。また、適宜精製してガラクト
オリゴ糖の純度を高めたものを用いてもよい・ことは言
うまでもない。The above-mentioned galactooligosaccharide, which is an active ingredient of the constipation preventive/therapeutic agent for domestic animals of the present invention, can be obtained by a method in which β-galactosidase of Aspergillus oryzae is applied to lactose (Japanese Patent Publication No. 58-1989).
20266), a method using Cryptococcus yeast (Japanese Unexamined Patent Publication No. 60-251896), and the like. According to these production methods, in addition to about 20 to 60% of galactooligosaccharides, disaccharides mainly consisting of unreacted lactose and by-product glucose,
A solution of a sugar mixture containing monosaccharides such as galactose is obtained. Although this can be used as it is in the constipation preventive/therapeutic agent for domestic animals of the present invention, β-
It is also possible to use one in which the content of unreacted lactose is reduced by the action of galactosidase. It goes without saying that galacto-oligosaccharides with increased purity may be used by appropriately purifying them.
ガラクトオリゴ糖を家畜用便秘予防・治療剤として利用
するには、上述のようにして得られる糖混合物またはそ
の精製物をそのまま紅白投与するか、飼料または飲料水
に混合して投与する。ガラクトオリゴ糖は弱い甘味を呈
し、水によく溶けるから、飼料または飲料水に混合して
投与しても家畜が忌避することはない。In order to utilize galactooligosaccharide as a constipation preventive/therapeutic agent for livestock, the sugar mixture obtained as described above or its purified product is administered as is or mixed with feed or drinking water. Galactooligosaccharides have a weak sweet taste and are highly soluble in water, so livestock will not be turned off by them even if they are mixed with feed or drinking water and administered.
投与量は、１日あたり約０．０２〜１．０ ｇ／ｋ（、
特に０．０６〜０．４ ｇ／Ｍが適当である。The dosage is approximately 0.02-1.0 g/k (,
Particularly suitable is 0.06 to 0.4 g/M.
以下、実施例を示して本発明を説明する。 Hereinafter, the present invention will be explained with reference to Examples.
実施例１
食品グレードの乳糖４ｋｇを２．４Ｌの熱水に溶解し、
アスペルギルス・オリゼのβ−ガラクトシダーゼを８万
単位加えて６７°Ｃで２時間反応させた。その後、反応
液を９５°Ｃに１０分間加熱して酵素を失活させ、固形
分濃度５０％まで希釈した後、ストレプトコッカス・サ
ーモフィルスより調製したβ−ガラクトシダーゼを５ｏ
ｏｏ単位添加し、４５°Ｃで４００時間反応せた。Example 1 4 kg of food grade lactose was dissolved in 2.4 L of hot water,
80,000 units of Aspergillus oryzae β-galactosidase was added and reacted at 67°C for 2 hours. Thereafter, the reaction solution was heated to 95°C for 10 minutes to inactivate the enzyme, diluted to a solid content concentration of 50%, and β-galactosidase prepared from Streptococcus thermophilus was added at 50°C.
0 units were added and the reaction was carried out at 45°C for 400 hours.
その後、反応液を９０’Ｃ！に１０分間加熱して酵素を
失活させ、粉炭とセライトを加えてろ過し、イオン交換
樹脂を用いてろ液を脱塩処理した。After that, the reaction solution was heated to 90'C! The mixture was heated for 10 minutes to inactivate the enzyme, filtered by adding powdered charcoal and Celite, and the filtrate was desalted using an ion exchange resin.
得られた糖液の濃縮液（ガラクトオリゴ糖２７．８％、
二糖類２１．１％、単糖類２６．１％、水分２５％）を
、家畜用便秘予防・治療剤として以下の試験に供した。The obtained concentrated sugar solution (galactooligosaccharide 27.8%,
(21.1% disaccharide, 26.1% monosaccharide, 25% water) was used in the following test as a constipation preventive/therapeutic agent for livestock.
試験例１
妊娠５０日より分娩１０日後までの母豚６０頭の中で、
便秘をしている２０頭を２群に分け、Ａ群１０頭に対し
て消化機能異常治療剤・プリンペラン（藤沢薬品製）を
、１日１回２５Ｂを２日間注射した。Ｂ群の１０頭に対
しては、実施例１による糖液４０１を１日１回、３日間
、配合飼料にふりかけて与えた。Test Example 1 Among 60 sows from the 50th day of pregnancy to the 10th day after parturition,
Twenty constipated animals were divided into two groups, and 10 animals in group A were injected with Primeran (manufactured by Fujisawa Pharmaceutical), a treatment for digestive dysfunction, and 25B once a day for two days. For the 10 animals in Group B, sugar solution 401 according to Example 1 was sprinkled on the mixed feed once a day for 3 days.
両群の治療経過を表１に示した（数値は頭数）。The treatment progress of both groups is shown in Table 1 (numbers are number of animals).
表１
実施例２
食品グレードの乳糖４ｋｌを２．４１の熱水に溶解し、
アスペルギルス・オリゼのβ−ガラクトシダーゼを８万
単位加えて６７°Ｃで２時間反応させた。その後、反応
液を９５°Ｃで１０分間加熱して、酵素を失活させ、活
性炭とセライトを加えて濾過し、固形分７５％まで濃縮
した。Table 1 Example 2 4kl of food grade lactose was dissolved in 2.41g hot water,
80,000 units of Aspergillus oryzae β-galactosidase was added and reacted at 67°C for 2 hours. Thereafter, the reaction solution was heated at 95° C. for 10 minutes to inactivate the enzyme, filtered with activated carbon and Celite, and concentrated to 75% solids.
得られた糖液（ガラクトオリゴ糖２２．５％、二糖類３
３．７％、単糖類１８．８％）を、家畜用便秘予防・治
療剤として以下の試験に供した。The obtained sugar solution (22.5% galactooligosaccharides, 3 disaccharides)
3.7%, monosaccharides 18.8%) was subjected to the following test as a constipation preventive/therapeutic agent for livestock.
試験例２
飼育母豚２００頭を３群に分け、Ａ群には通常の完全配
合飼料を□与えた。Ｂ群には、上記飼料に実施例２によ
る糖液を１日１回、１０１ふりかけて与えた。０群に対
しては、上記飼料に大麦粉砕物を２０％添加したものを
与えた。Test Example 2 200 breeding sows were divided into 3 groups, and group A was fed a normal complete compound feed. Group B was fed the above feed with 101 sprinkling of the sugar solution according to Example 2 once a day. Group 0 was given the above feed with 20% pulverized barley added.
上記条件で飼育中に便秘になった豚の比率は、Ａ群、Ｂ
群、０群、それぞれ３１．４％、６．６％、１１．７％
であった。The percentage of pigs that became constipated while being raised under the above conditions was as follows:
group, 0 group, 31.4%, 6.6%, 11.7%, respectively.
Met.
試験例の結果から明らかなように、本発明の家畜用便秘
予防・治療剤によれば、飼料にふりかける程度の簡単な
投与法によって、家畜になんらのストレスも与えること
なしに、便秘を予防および治療することができる。As is clear from the results of the test examples, the constipation prevention and treatment agent for livestock of the present invention can prevent and treat constipation without causing any stress to livestock by a simple administration method such as sprinkling it on feed. Can be treated.
本発明の便秘予防・治療剤の特に有利な点は、その有効
成分が糖類であって好ましくない副作用や嗜好阻害がな
く、連続投与が可能なことである。A particularly advantageous point of the constipation preventive/therapeutic agent of the present invention is that its active ingredient is a saccharide, so there are no undesirable side effects or preference inhibition, and continuous administration is possible.
Claims (1)
ｌはガラクトース残基、Ｇｌｃはグルコース残基、ｎは
１〜４の整数を、それぞれ表わす）で示されるオリゴ糖
を有効成分として含有することを特徴とする家畜用便秘
予防・治療剤。General formula Gal-(Gal)n-Glc (wherein Ga
1. A prophylactic/therapeutic agent for constipation for livestock, characterized in that it contains as an active ingredient an oligosaccharide represented by the following formulas: l represents a galactose residue, Glc represents a glucose residue, and n represents an integer from 1 to 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62309727A JP2571702B2 (en) | 1987-12-09 | 1987-12-09 | Prevention and treatment of constipation for pigs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62309727A JP2571702B2 (en) | 1987-12-09 | 1987-12-09 | Prevention and treatment of constipation for pigs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01151520A true JPH01151520A (en) | 1989-06-14 |
| JP2571702B2 JP2571702B2 (en) | 1997-01-16 |
Family
ID=17996571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62309727A Expired - Fee Related JP2571702B2 (en) | 1987-12-09 | 1987-12-09 | Prevention and treatment of constipation for pigs |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2571702B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072123A1 (en) * | 2001-03-02 | 2002-09-19 | Beppu, Kunihide | Preventives or remedies for tumor or papillomaviral diseases |
| WO2007138905A1 (en) | 2006-05-30 | 2007-12-06 | Ensuiko Sugar Refining Co., Ltd. | Intestinal eosinophil-suppressing composition |
| CN102389028A (en) * | 2011-11-10 | 2012-03-28 | 青岛根源生物技术集团有限公司 | Feed additive and applications of feed additive in constipation of sow |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6363366A (en) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | Healthy food for promoting control of intestinal function |
-
1987
- 1987-12-09 JP JP62309727A patent/JP2571702B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6363366A (en) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | Healthy food for promoting control of intestinal function |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072123A1 (en) * | 2001-03-02 | 2002-09-19 | Beppu, Kunihide | Preventives or remedies for tumor or papillomaviral diseases |
| WO2007138905A1 (en) | 2006-05-30 | 2007-12-06 | Ensuiko Sugar Refining Co., Ltd. | Intestinal eosinophil-suppressing composition |
| CN102389028A (en) * | 2011-11-10 | 2012-03-28 | 青岛根源生物技术集团有限公司 | Feed additive and applications of feed additive in constipation of sow |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2571702B2 (en) | 1997-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69533593T2 (en) | PREPARATIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDER CONTAINING ARABINOGALACTAN AND POLYPHENOLS OF LARIX. | |
| EP1413303B1 (en) | Swine growth promoters and method of promoting swine growth | |
| WO1996003150B1 (en) | Compositions containing hemicelluloses and polyphenols for treating gastrointestinal disorders | |
| JP3514955B2 (en) | Calcium absorption enhancing composition | |
| US4873229A (en) | Galacto-oligosaccharide containing feed | |
| TWI291351B (en) | Pharmaceutical composition for lowering blood-sugar | |
| JPWO2007138905A1 (en) | Intestinal Eosinophil Inhibitory Composition | |
| FI73121C (en) | FOLLOW-UP FODER OCH TILLSATSAEMNE FOER ANVAENDNING DAERI. | |
| US4788065A (en) | Feeding method in breeding sows | |
| EP1014808B1 (en) | Fatty acids as a diet supplement | |
| JP2000262247A (en) | Immunomodulation agent, immunomodulation food and immunomodulation feed | |
| JPH01151520A (en) | Preventive and remedy for constipation of domestic animal | |
| Young | Experimental Approach to Diabetes Mellitus | |
| JP3279694B2 (en) | Mineral absorption enhancer containing lactulose oligosaccharide as active ingredient | |
| JPH05219897A (en) | Galactooligosaccharide-containing feed | |
| JPH08509211A (en) | Immunostimulating / infection-preventing agent containing two or more kinds of bacteria, egg white and garlic | |
| Gledhill et al. | A spontaneous enterococcal disease of mice and its enhancement by cortisone | |
| RU2377005C1 (en) | Method of treating gastrointestinal diseases in calves | |
| JPH06228181A (en) | New oligosaccharide comprising glucuronic acid, its production and utilization | |
| JP3572103B2 (en) | Secondary bile acid lowering agent | |
| JPH06105651A (en) | Production of cow's milk having low lactose content | |
| US7074774B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of pharmaceutical useful for treating cardio-cerebrovascular anoxemia | |
| JP3279695B2 (en) | Mineral absorption enhancer containing branched galactooligosaccharide as active ingredient | |
| SU1761098A1 (en) | Method fro new-born calves raising | |
| KR950009945B1 (en) | "veterinary preparation containing an antibiotic mixture of gentamicin and lincomycin as an additive to drinking water or animal feed and its use in pig breeding |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |